Why invest in Medicortex Finland Plc?
TBI is the leading cause of central nervous system impairment and there is no reliable way to detect mild injuries - yet! Here's why Medicortex could solve the problem:
- The company’s biggest strength is in the proprietary idea
itself. As per the company’s assessment it is innovative and something that
does not exist at the moment, providing a competitive advantage.
test – detecting a biomarker in a non-invasive sample (urine or saliva) – will address a TBI point of care (POC) diagnostics market that is estimated to exceed €2
new biomarker and the technology surrounding it has been protected by
several patent applications. Some patents have already been granted.
- The company has comprehended that there is a huge need for new innovative and efficient diagnostic tools.
company’s management has noted that the brain injury diagnostics market is
large and the potential customer base vast.
- Medicortex has received several awards and recognitions for its
innovation, as well as research funding from major funders, such as the
US Department of Defense’s medical research funds showing that Medicortex has gained much
Investments will be used primarily for development of the diagnostic kit.
- Basic development including preclinical trial and proof-of-concept human testing has been done.
company has completed three clinical trials where the biomarker was
discovered. The first study included 24 subjects (TBI and healthy), the second
contained 69 (TBI, orthopedic injury, healthy), and the third 58 (children with TBI/healthy). The recruitments were carried out in three Finnish
hospitals: Tyks, Satakunta Central Hospital, Vaasa Central Hospital.
Investments always carry risks - Invest responsibly
Go back to Investors page